Monday Moves [ 11/26/12]: Angiodynamics Announces New CFO; AtriCure Names New CEO


Monday Moves [11/26/12]

Angiodynamics Announces New CFO; AtriCure Names New CEO; New Appointment at PwC
Joseph Gersuk to Retire From AngioDynamics; Mark T. Frost Appointed Chief Financial Officer
AngioDynamics, a provider of minimally invasive medical devices for vascular access, surgery, peripheral vascular disease, and oncology, has announced that executive vice president and chief financial officer Joseph Gersuk will retire from the company on January 31, 2013. He will be succeeded by Mark T. Frost, who was most recently chief financial officer and senior vice president of administration of Albany Molecular Research Inc. (AMRI) Frost has 25 years of global financial, administrative and operational experience, with a strong background in the healthcare industry. Prior to AMRI, he served five years as vice president of finance at Smith & Nephew Endoscopy, a global medical device division of Smith & Nephew PLC. [Angiodynamics]

Michael H. Carrel, AtriCure, Inc. President and Chief Executive Officer (Photo: Business Wire)

AtriCure Names Michael H. Carrel President and Chief Executive Officer
AtriCure Inc., a medical device company that manufactures cardiac surgical ablation systems for the treatment of atrial fibrillation (AF), and systems for the exclusion of the left atrial appendage, has announced that Michael Carrel has been appointed president and CEO of the company. Carrel was most recently the president and CEO of Vital Images, a publicly-traded medical imaging software company from 2008 until it was sold to Toshiba in 2011. He stayed on as CEO of the new business unit within Toshiba until 2012, when the integration was successfully completed. He originally joined Vital Images in January 2005 as chief operating and financial officer. During his time at Vital, Mike worked extensively with surgeons, cardiologists, radiologists, oncologists, and neurologists in developing and taking new products to market. Under his leadership, the company grew revenue and profitability, increased global market share, expanded its presence to over 90 countries, and raised $100 million in equity financing. [AtriCure]
Pwc Appoints Michael Swanick as Global Pharmaceutical and Life Sciences Industry Leader
PwC has announced that Michael Swanick has been appointed as Global Pharmaceutical and Life Sciences Industry leader, succeeding Simon Friend.  As the global practice leader, Swanick is responsible for the strategy and direction of the firm's multinational pharmaceutical, medical device, and life sciences practice, which is comprised of approximately 4700 industry dedicated professionals around the world. A 28-year veteran of PwC, Swanick most recently held the position of PwC's U.S. Pharmaceutical and Life Sciences Leader and Global Tax Leader for the practice. He will continue to serve in this capacity, while taking on additional global responsibilities for the firm. [PwC]


No votes yet